Anal Chem. 2019 Aug 6;91(15):9893-9900. doi: 10.1021/acs.analchem.9b01561. Epub 2019 Jul 10.
Prostate cancer is the most common type of cancer in men, and kinases are heavily pursued as drug targets for anticancer therapy. In this study, we applied our recently reported parallel-reaction-monitoring (PRM)-based targeted proteomic method to examine the reprogramming of the human kinome associated with bone metastasis of prostate cancer in vitro. The method displayed superior sensitivity over the shotgun-proteomic approach, and it facilitated the quantification of the relative expression of 276 kinase proteins in a pair of bone metastatic prostate cancer cells. Among the differentially expressed kinases, mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4) stimulates the migration and invasion of cultured prostate cancer cells, partially by modulating the activity of secreted matrix metalloproteinases 9 (MMP-9). We also found that the upregulation of MAP4K4 in metastatic prostate cancer cells is driven by the proto-oncogene. Cumulatively, we identify MAP4K4 as a potential promoter for prostate cancer metastasis in vitro.
前列腺癌是男性最常见的癌症类型,激酶被广泛用作抗癌治疗的药物靶点。在这项研究中,我们应用了最近报道的平行反应监测(PRM)为基础的靶向蛋白质组学方法,研究与前列腺癌骨转移相关的人类激酶组的重编程。与 shotgun-proteomic 方法相比,该方法具有更高的灵敏度,并且能够定量分析 276 种激酶蛋白在一对骨转移前列腺癌细胞中的相对表达。在差异表达的激酶中,丝裂原活化蛋白激酶激酶激酶激酶 4(MAP4K4)通过调节分泌型基质金属蛋白酶 9(MMP-9)的活性,刺激培养的前列腺癌细胞的迁移和侵袭。我们还发现,转移性前列腺癌细胞中 MAP4K4 的上调是由原癌基因驱动的。综上所述,我们确定 MAP4K4 是体外前列腺癌转移的一个潜在促进因子。